Weekly Recap: Tozorakimab cuts COPD events and ENHERTU improves PFS
AstraZeneca PLC (LSE:AZN) reported mixed clinical news: robust positive Phase 3 and Phase 2 results across COPD (tozorakimab), HER2—mutant NSCLC (ENHERTU), TAGRISSO long—term survival and Imfinzi+tarlatamab, alongside a failed SERENA—4 trial, while CEO Pascal Soriot warned MFN pricing risks R&D cut…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.